Intermittent versus maintenance iron therapy in children on hemodialysis: A randomised study

Pediatric Nephrology

Volumn 19, Issue 1, 2004, Pages 77-81

  Ruiz Jaramillo, Ma de la Cruz ^a,b   Guízar Mendoza, Juan Manuel ^a   Gutiérrez Navarro, María de Jesús ^a   Dubey Ortega, Luis Antonio ^a   Amador Licona, Norma ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b NONE   (Mexico)

Author keywords

Anemia; Dextran; Ferritin; Iron overload; Renal failure

Indexed keywords

ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; IRON; IRON DEXTRAN; TRANSFERRIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG INTERMITTENT THERAPY; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; IRON DEFICIENCY ANEMIA; IRON OVERLOAD; IRON THERAPY; KIDNEY FAILURE; LOW DRUG DOSE; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TRANSFERRIN BLOOD LEVEL; TREATMENT OUTCOME;

ADOLESCENT; ANEMIA, IRON-DEFICIENCY; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FERRITINS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; KIDNEY FAILURE, CHRONIC; MALE; TRANSFERRIN; TREATMENT OUTCOME;

EID: 0346007907     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-003-1288-9     Document Type: Article

References (31)

1. Nimer SD, Wocott DL (1991) Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy, and nervous system effects. Ann Intern Med 114:402-416
2. Warady BA, Jabs K (1995) Nuevas hormonas en el arsenal terapéutico de la insuficiencia renal crónica: hormona del crecimiento y eritropoyetina. Pediatr Clin North Am 6:1466-1480
3. Harmon WE, Jabs KL (1999) Hemodialysis. In: Barrat TM, Avner ED, Harmon WE (eds) Pediatric nephrology, 4th edn. Lippincott Williams and Wilkins, USA, pp 1277-1279
4. Nissenson AR, Strobos J (1999) Iron deficiency in patients with renal failure. Kidney Int 55 [Suppl 69]:S18-S21
5. Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, Ogden DA (1989) Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 35:712-716
6. Fishbane S, Frei GL, Maesaka J (1995) Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26:41-46
7. Macdougall IC (1999) Strategies for iron supplementation: oral versus intravenous. Kidney Int 55 [Suppl 69]:S61-S66
8. Ifudu O (1998) Parenteral iron: pharmacology and clinical use. Nephron 80:249-256
9. Fishbane S, Mittal SK, Maesaka JK (1999) Beneficial effects of iron therapy in renal failure patients on hemodialysis. Kidney Int 55 [Suppl 69]:S67-S70
10. Macdougall IC, Chandler G, Orlaith E, Harchowal J (1999) Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. Am J Kidney Dis 34 [Suppl 2]:S40-S46
11. Seeherunvong W, Rubio L, Abitbol CL, Montane B, Strauss J, Diaz R, Zilleruelo G (2001) Identification of poor responders to erythropoietin among children undergoing hemodialysis. J Pediatr 138:710-714
12. Bristian BR, Khaodhiar L (1999) The systemic inflammatory response and its impact on iron nutriture in end-stage renal disease. Am J Kidney Dis 34 [Suppl 2]:S35-S39
13. Abbas AK, Lichtman AH, Pober JS (1999) Inmunología celular y molecular, 3er edn. Interamericana McGraw-Hill, pp 234-253, 275-308
14. Eschbach JW, Adamson JW (1999) Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy. Kidney Int 55 [Suppl 69]:S35-S43
15. Park L, Uhthoff T, Tierney M, Nadler S (1998) Effect of an intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients. Am J Kidney Dis 31:835-840
16. Kalantar-Zadeh K, Don BR, Rodríguez RA (2001) Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis 37:564-572
17. National Kidney Foundation-Dialysis Outcomes Quality Initiative (1997) Clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 30:192-240
18. Tarng DCH, Huang TP, Chen TW, Yang WCH (1999) Erythropoietin hyporesponsiveness: from iron deficiency to iron overload. Kidney Int 55 [Suppl 69]:S107-S118
19. Morgan HEG, Gautam M, Geary DF (2001) Maintenance intravenous iron therapy in pediatric hemodialysis patients. Pediatr Nephrol 16:779-783
20. Macdougall IC, Cavill I, Hulme B, Bain B, McGregor E, McKay P, Sanders E, Coles GA, Williams JD (1992) Detection of functional iron deficiency during erythropoietin treatment: a new approach. BMJ 304:225-226
21. Owen WF, Szczech L, Johnson C, Frankenfield D (1999) National perspective on iron therapy as a clinical performance measure for maintenance hemodialysis patients. Am J Kidney Dis 34 [Suppl 2]:S5-S11
22. Besarab A, Kaiser J, Frinak S (1999) A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 34:21-28
23. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A (2000) Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11:530-538
24. Sepandy F, Kindal K, West M, Hirsch D (1996) Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant 11:2319-2322
25. Taylor JE, Peat N, Porter C, Morgan AG (1996) Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 11:1079-1083
26. St Peter WL, Lambrecht LJ, Macres M (1996) Randomized cross-over study of adverse reactions and cost implications of intravenous push compared with infusion of iron dextran in hemodialysis patients. Am J Kidney Dis 28:523-528
27. Flores FX, Jabs K, Harmon WE, Somers MJG (1999) Safety and efficacy of intravenous iron dextran in pediatric hemodialysis patients. Pediatr Res 45:331A
28. Tenbrock K, Müller-Berghaus J, Michalk D, Querfeld U (1999) Intravenous iron treatment of renal anemia in children on hemodialysis. Pediatr Nephrol 13:580-582
29. VanWyck DB (1989) Iron management during recombinant human erythropoietin therapy. Am J Kidney Dis 14 [Suppl 1]:9-13
30. Pocock SJ (1993) Monitoring trial progress. In: Pocock SJ (ed) Clinical trial. A practical approach. Wiley, 142-159
31. Rocco MV, Bedinger MR, Milam R (2001) Duration of dialysis and its relationship to dialysis adequacy, anemia management, and serum albumin level. Am J Kidney Dis 38:813-823